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Background: The present study was undertaken to investigate the effect of statins plus omega-3 
polyunsaturated fatty acids (PUFAs) on endothelial function and lipid proﬁ  le in South Asians 
with dyslipidemia and endothelial dysfunction, a population at high risk for premature coronary 
artery disease.
Methods: Thirty subjects were randomized to rosuvastatin 10 mg and omega-3-PUFAs 4 g 
or rosuvastatin 10 mg. After 4 weeks, omega-3-PUFAs were removed from the ﬁ  rst group 
and added to subjects in the second group. All subjects underwent baseline, 4-, and 8-week 
assessment of endothelial function and lipid proﬁ  le.
Results: Compared to baseline, omega-3-PUFAs plus rosuvastatin improved endothelial-dependent 
vasodilation (EDV: −1.42% to 11.36%, p = 0.001), and endothelial-independent vasodilation (EIV: 
3.4% to 17.37%, p = 0.002). These effects were lost when omega-3-PUFAs were removed (EDV: 
11.36% to 0.59%, p = 0.003). In the second group, rosuvastatin alone failed to improve both EDV 
and EIV compared to baseline. However, adding omega-3-PUFAs to rosuvastatin, signiﬁ  cantly 
improved EDV (−0.66% to 14.73%, p = 0.001) and EIV (11.02% to 24.5%, p = 0.001). Addition 
of omega-3-PUFAs further improved the lipid proﬁ  le (triglycerides 139 to 91 mg/dl, p = 0.006, 
low-density lipoprotein cholesterol 116 to 88 mg/dl, p = 0.014).
Conclusions: Combined therapy with omega-3-PUFAs and rosuvastatin improves endothelial 
function in South Asian subjects with dyslipidemia and endothelial dysfunction.
Keywords: omega-3 fatty acids, endothelial function, South Asians, dyslipidemia, 
rosuvastatin
Introduction
Endothelium, as the major regulator of vascular homeostasis, exerts a number of 
vasoprotective effects, by maintaining the balance between vasodilation and vasocon-
striction, inhibition and stimulation of smooth muscle cell proliferation and migration, 
and thrombogenesis and ﬁ  brinolysis (Vane et al 1990; Galley and Webster 2004). 
Many of these effects are largely mediated by nitric oxide (NO), the most potent endog-
enous vasodilator. A defect in the synthesis, release, or activity of nitric oxide leads 
to endothelial dysfunction, an early marker for atherosclerosis (Bonetti et al 2003). 
Endothelial function can be easily measured noninvasively with Doppler ultrasonog-
raphy by assessing ﬂ  ow-mediated dilation (FMD) in the brachial artery after transient 
vascular occlusion (Faulx et al 2003; Corretti et al 2002). FMD serves as an index of 
NO bioavailability and vascular health.
The rapidly growing South Asian population in United States has one of the 
world’s highest rates of endothelial dysfunction, metabolic syndrome and premature 
coronary artery disease (CAD) irrespective of region, religion, gender, and education. 
This may be a result of genetic predisposition to high levels of lipoprotein (a), Vascular Health and Risk Management 2008:4(6) 1440
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small coronary arteries, low birth weight, in addition to 
environmental, nutritional and lifestyle factors (Bedi et al 
2006; Gupta et al 2006).
Epidemiological studies and clinical trials indicate that 
the intake of very-long-chain n-3 polyunsaturated fatty 
acids (omega-3 PUFAs) such as eicosapentaenoic acid 
(EPA) and docosahexaenoic acid (DHA) reduces the risk of 
cardiovascular mortality (Bjerregaard and Dyerberg 1988; 
Newmans et al 1993; GISSI 1999). The cardioprotective 
effects of omega-3 PUFAs are widespread and are mediated 
by several mechanisms, which include decreasing triglycer-
ide levels, increasing HDL levels, antiinﬂ  ammatory proper-
ties, antithrombotic properties, antiarrhythmic properties and 
endothelial relaxation properties (Das 2000; Calder 2004).
Statins, potent inhibitors of cholesterol biosynthesis, 
are indicated in the primary and secondary prevention 
of CAD. Their overall benefits suggest effects beyond 
cholesterol lowering that involve improving endothelial 
function, enhancing the stability of atherosclerotic plaques, 
decreasing oxidative stress and inﬂ  ammation and inhibiting 
the thrombogenic response (Liao and Laufs  2005).
The effect of a combined therapy of statins plus omega-3 
PUFAs on endothelial function in a South Asian population, 
particularly at high risk for premature CAD, has not been 
investigated so far. We designed a randomized controlled 
cross-over study to test the hypothesis that omega-3 PUFAs 
intake plus rosuvastatin improves endothelial function in 
South Asians with dyslipidemia.
Methods
Study population
South Asian subjects (originating or having ancestry from 
India, Pakistan, or Bangladesh) now living in the New York 
metropolitan area were recruited for a protocol approved 
by our Institutional Review Board. Informed consent was 
obtained from each patient and the study protocol conforms 
to the ethical guidelines of the 1975 Declaration of Helsinki. 
To be eligible for the screening phase of the study, the sub-
jects had to be 25 to 80 years old, and have a diagnosis of 
dyslipidemia, deﬁ  ned for the purpose of this study as a plasma 
low-density lipoprotein (LDL) cholesterol  100 mg/dl, 
and/or plasma triglyceride  150 mg/dl, with or without 
established CAD. All subjects deemed eligible after the 
screening phase underwent endothelial function assessment 
including endothelium-dependent vasodilation (EDV) and 
endothelium-independent vasodilation (EIV) with brachial 
artery ultrasound, as described below. Those who had an 
abnormal endothelial function, deﬁ  ned as an EDV less than 
7%, were retained for the active phase of the study. Healthy 
arteries typically show an increase in diameter in the range 
of 5% to 20%.
Study design
After the initial endothelial function assessment, patients were 
randomized in a crossover design between 2 drug regimens: 
rosuvastatin 10 mg along with omega-3 fatty acid supplements 
(Fish oil capsules 4.53 g DHA/EPA, N3 Oceanic Inc., Palm, 
PA, USA) (Group 1) or rosuvastatin 10 mg alone (Group 2) 
as shown in Figure 1. After 4 weeks, the omega-3 PUFAs 
supplements were removed from the treatment of Group 1 
and added to the subjects in Group 2. Each patient served as 
his own control. The omega-3 fatty acid supplement capsules 
contained 430 mg EPA, 325 mg DHA, gelatin, glycerine, 
puriﬁ  ed water, and natural lemon ﬂ  avor as other ingredients. 
Subjects received 2 capsules three times per day. Patients 
taking statin medication were asked to stop that medication 
for four weeks before entering the study. All subjects main-
tained the same medication other than the study medication 
throughout the duration of the study. Compliance with the 
medication was assessed by pill count at each visit and at 
the end of the study.
Assessment of endothelium-dependent 
and endothelium-independent 
vasodilation
The endothelial function was evaluated according to the 
guidelines for the ultrasound assessment of ﬂ  ow-mediated 
vasodilatation of the brachial artery (Corretti et al 2002), as 
previously described from our laboratory (Barua et al 2002; 
Staniloae et al 2006). Although no gold standard for the 
measurement of endothelial function exist, the measurement 
of ﬂ  ow-mediated vasodilation in the brachial artery, assessed 
with Doppler ultrasound, has become the clinical technique of 
choice for the evaluation of endothelial function. The method 
was validated and widely used in numerous clinical studies 
(Faulx et al 2003; Sorensen et al 1995; Donald et al 2008). All 
measurements were performed early in the morning. Subjects 
were requested to abstain from any food or drink for at least 
8 hours (overnight) and not use tobacco on the morning of 
the evaluation. All vasoactive medication was withheld on 
the morning of the study. On arrival subjects were allowed 
to rest in a supine position for 20 minutes. Baseline blood 
pressure and heart rate were recorded and blood was collected 
from the antecubital vein. This was followed by an in vivo 
assessment of endothelial function by using ultrasonography 
to measure the brachial artery diameter at rest, during reactive Vascular Health and Risk Management 2008:4(6) 1441
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hyperemia (leading to ﬂ  ow-mediated endothelium-dependent 
vasodilatation), and after administration of 0.4 mg of sublingual 
nitroglycerin (an endothelium-independent vasodilator). After 
baseline imaging was performed by scanning the brachial 
artery in a longitudinal fashion, a pneumatic cuff was inﬂ  ated 
around the right forearm to 50–60 mmHg above the systolic 
pressure (≈200 mmHg) for 5 minutes. The cuff was then 
released and the artery continuously imaged for 5 minutes. 
After an additional 5 minutes of recuperation, a new baseline 
imaging was obtained followed by the administration of 0.4 mg 
nitrogycerin and continuously imaging for other 5 minutes. 
Flow-mediated endothelium dependent vasodilation (EDV) 
was calculated by dividing the maximum vessel diameter at 
50 to 60 seconds after cuff deﬂ  ation by the average baseline 
diameter. Endothelium-independent vasodilation (EIV) was 
measured as the maximum vessel diameter at 3 to 4 minutes 
after nitroglycerin administration divided by average baseline 
diameter. The arterial diameter was measured by using 
ultrasonic calipers for 4 cardiac cycles for each condition and 
then averaged. Flow-mediated vasodilation was expressed 
as the absolute change in diameter (in millimeters), and as 
the percent increase in diameter from baseline. All ultraso-
nographic scans were obtained by the same operator using 
the same equipment (Acuson L10 6- to 11-MHz transducer 
and Acuson Aspen System). All brachial artery scans were 
read by the same experienced ultrasonographer and validated 
by a second independent reader, both of whom were blinded 
to both the identity of the participants as well as the stage of 
the experiment. Across 100 observations performed in our 
laboratory by 2 observers, a diameter difference of 0.2 mm 
was estimated correctly in 72% of the cases. There was an 
interobserver variability of 0.1 mm in 28% of the cases. There 
was no difference larger than 0.2 mm between the 2 observers. 
The intraobserver variability was 0.82.
Laboratory measurements
Fasting blood samples were obtained at baseline and at the 
end of each drug regimen (Week 4 and Week 8). Plasma 
analysis for the lipid proﬁ  le, fasting glucose, C-reactive 
protein (CRP), hemoglobin A1C (Hb A1C), erythrocyte 
sedimentation rate (ESR), and ﬁ  brinogen was done in the 
hospital’s clinical laboratory. For the rest of the studies blood 
Baseline Measurements (endothelial 
function and lipid profile) in 30 South 
Asian patients
CROSSOVER
4 weeks
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(n = 16)
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Figure 1 Study design: An open-label, randomized cross-over study. Group 1 represents patients starting with rosuvastatin plus omega-3 PUFAs, Group 2 represents patients 
starting with rosuvastatin only.
Abbreviations: Ro, rosuvastatin; Omega-3 PUFAs, Omega-3 polyunsaturated fatty acids.Vascular Health and Risk Management 2008:4(6) 1442
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was collected in Vacutainer tubes for serum separation and 
centrifuged at 3000 rpm for 15 minutes (4 °C). The serum 
was collected and stored at −70 °C until use.
Adiponectin ELISA
Adiponectin concentrations in serum samples of patients 
participating in the study were measured using an ELISA 
kit (Linco Research, St. Charles, MO, USA) according 
to the manufacturer’s instructions. Serum samples were 
diluted 500 times in the assay diluent buffer before analysis 
in order to fall within the dynamic range of the assay.
Statistical analysis
Analyses were performed with SPSS software (version 10.0; 
SPSS Inc., Chicago, IL, USA). Sample size calculations 
indicated that, to detect a mean difference in EDV of 2% on 
the study medication, using a croos-over design, 16 subjects 
would need to complete the study (α statistic, 0.05; 
power  0.8). Data are presented as mean ± SD. Wilcoxon 
signed-rank test was used to compare changes in outcome 
variables for endothelial function in response to treatment 
or with the wash out period. Paired or unpaired t test or chi 
square test were used to compare demographic baseline 
characteristics and laboratory values. Statistical signiﬁ  cance 
was set for p   0.05.
Results
Thirty of thirty-four screened subjects completed the study. 
Three subjects failed to fulﬁ  ll eligibility criteria (endothelial 
function within normal range) and one was lost to follow-up. 
The study medication was well tolerated by all subjects 
and no bleeding or muscle symptoms were reported. Their 
mean age was 51 (range, 27 to 78 years). Their demographic 
and metabolic characteristics are summarized in Table1. 
The complete results of the assessment of the endothe-
lial function are summarized in Table 3. For subjects in 
Group 1 (n = 14), compared to baseline, omega-3 PUFAs 
plus rosuvastatin improved endothelial-dependent vasodila-
tion (EDV: −1.42% to 11.36%, p = 0.001) (Figure 2), and 
endothelial-independent vasodilation (EIV: 3.4% to 17.37%, 
p = 0.002) (Figure 3). When omega-3 PUFAs were removed, 
these effects were lost (EDV: 11.36% to 0.59%, p = 0.003) 
(Figure 2). In Group 2 (n = 16), rosuvastatin alone failed to 
improve both EDV (−2.49% to −0.66%, p = 0.48) and EIV 
(10.31% to 11.02%, p = 0.6) compared to baseline. How-
ever, when omega-3 PUFAs were added to rosuvastatin, 
there was a signiﬁ  cant improvement in EDV (−0.66% to 
14.73%, p = 0.001) (Figure 2) and EIV (11.02% to 24.5%, 
p = 0.001) (Figure 3). Addition of omega-3 PUFAs further 
improved the lipid proﬁ  le in both groups (Figure 4). In 
group 1 total cholesterol decreased from 191 to 153 mg/dl 
(p = 0.001), triglycerides from 139 to 91 mg/dl (p = 0.006), 
Table 1 Baseline characteristics of the study subjects
Characteristics Group 1 (n = 14) Group 2 (n = 16) P value
Age (years), mean (range) 51 (27–78) 52 (28–73) NS
Gender: Male (n, %) 12 (86) 11 (69) NS
  Female (n, %) 2 (14) 5 (31) NS
BMI, mean (kg/m2) 27 ± 4.2 27.2 ± 4.7 NS
Dyslipidemia (n, %) 14 (100) 16 (100) NS
Metabolic syndrome (n, %) 11 (79) 16 (100) NS
CAD (n, %) 9 (64) 11 (69) NS
Diabetes (n, %) 5 (36) 5 (31) NS
HTN (n, %) 9 (64) 12 (75) NS
Medications
  ASA (n, %) 9 (64) 13 (81) NS
  Clopidogrel (n, %) 7 (50) 8 (50) NS
  Beta blocker (n, %) 9 (64) 9 (56) NS
  ACE inhibitor or ARB (n, %) 7 (50) 10 (63) NS
  Statin 4-week washout prior 
to randomization
4-week washout prior to 
randomization
Notes: Group 1 represents patients starting with rosuvastatin plus omega-3 PUFAs, Group 2 represents patients starting with rosuvastatin only. Data are presented as n or 
mean ± SD. Comparison between groups was done by chi-square test or t-test for age and BMI.
Abbreviations: NS, nonsigniﬁ  cant; BMI, body mass index; CAD, coronary artery disease; HTN, hypertension;  ASA, aspirin;  ACE, angiotensin-converting enzyme;  ARB, angiotensin 
receptor blocker; PUFAs, polyunsaturated fatty acids; SD, standard deviation.Vascular Health and Risk Management 2008:4(6) 1443
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and LDL 116 to 88 mg/dl (p = 0.014). In group 2 total 
cholesterol decreased from 184 to 139 mg/ dl (p   0.001),  
triglycerides from 141 to 103 mg/dl (p = 0.013), and LDL 
from 109 to 76 mg/dl (p = 0.002). There were no signiﬁ  -
cant differences in the CRP, ESR, and ﬁ  brinogen levels 
(Table 2). Nevertheless a tendency of decreasing in ESR was 
noted in group 2 without reaching statistical signiﬁ  cance. 
Neither rosuvastatin nor the combination treatment affected 
the levels of adiponectin (Table 2).
Discussion
This study illustrates that the addition of omega-3 PUFAs 
to rosuvastatin in a high-risk population (South Asians) 
with dyslipidemia improves EDV and EIV as well as the 
lipid proﬁ  le. Withdrawal of omega-3 PUFAs treatment is 
associated with a return of the endothelial function back 
to the baseline, in spite of continuing the treatment with 
rosuvastatin.
Several studies have shown that South Asians are an 
emerging risk group for CAD as compared with other ethnicities 
(Bedi et al 2006; Gupta et al 2006). Numerous factors, includ-
ing a high prevalence of conventional risk factors (smoking, 
diabetes, hypertension, etc.), insulin resistance, metabolic 
syndrome, low birth weights, and genetic predisposition, have 
been shown to be responsible for this. The INTERHEART 
case-control study found that the population-attributable risk 
in the South Asian region is 58.7% for dyslipidemia, 37.4% 
for smoking, 37.7% for abdominal obesity, 29.6% for hyper-
tension, 11.8% for diabetes, and 15.9% for psychological risk 
factors (Yusuf et al 2004). Our study group was representative 
of this high-risk population: 100% of patients were dyslipid-
emic, 90% had metabolic syndrome (as deﬁ  ned by the ATP III 
criteria. (NCEP 2001), 70% had established CAD, 70% had 
hypertension, and 33% had a diagnosis of diabetes mellitus. 
Ninety percent of the patients screened for this study had 
severe endothelial dysfunction displaying a non-response or 
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Figure 2 Average endothelial dependent vasodilation percentage (EDV%) for groups 1 and 2 during each visit. Group 1 represents patients starting with rosuvastatin plus 
omega-3 PUFAs, Group 2 represents patients starting with rosuvastatin only. Data represent mean per group ± SE.
Notes: *indicates statistical signiﬁ  cance difference of average EDV% between each visit by Wilcoxon test.
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Figure 3 Average endothelial independent vasodilation percentage (EIV%) for groups 1 and 2 during each visit. Group 1 represents patients starting with rosuvastatin plus 
omega-3 PUFAs. Group 2 represents patients starting with rosuvastatin only. Data represent mean per group ± SE.
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Figure 4 Lipid proﬁ  le (including total cholesterol (TCh), high density lipoprotein (HDL), low density lipoprotein (LDL), and triglycerides (TG) for groups 1 and 2 at baseline 
(b), visit 1 (1), and visit 2 (2). Group 1 represents patients starting with rosuvastatin plus omega-3 PUFAs. Group 2 represents patients starting with rosuvastatin only. Data 
represent mean per group ± SE.
Note: *indicates statistical signiﬁ  cance (by t test) between each visit.
Table 2 Laboratory values
Group 1 Group 2
Baseline 1st visit 2nd visit Baseline 1st visit 2nd visit
Total cholesterol (mg/dl) 191 ± 44 153 ± 37* 159 ± 35* 184 ± 40 159 ± 54 139 ± 31*
HDL (mg/dl) 42 ± 12 43 ± 13 44 ± 14 41 ± 15 40 ± 10 43 ± 15
LDL (mg/dl) 116 ± 37 88 ± 29* 96 ± 36 109 ± 31 91 ± 41 76 ± 24*
Triglycerides (mg/dl) 139 ± 57 91 ± 40* 99 ± 27* 137 ± 71 141 ± 71 103 ± 36*
Glucose (mg/dl) 124 ± 54 130 ± 62 112 ± 30 104 ± 24 108 ± 39 110 ± 38
Hemoglobin A1C (%) 7.0 ± 2.2 7.0 ± 2.2 6.6 ± 1.8 6.5 ± 1.1 6.3 ± 1.0 6.2 ± 1.0
Fibrinogen (mg/dl) 357 ± 72 348 ± 70 338 ± 68 357 ± 87 352 ± 70 333 ± 69
C-reactive protein (mg/l) 0.36 ± 0.41 0.3 ± 0.36 0.34 ± 0.46 0.4 ± 0.46 0.25 ± 0.23 0.19 ± 0.17
ESR (mm/hr) 16 ± 13 14 ± 12 12 ± 9 18 ± 13 14 ± 11 9 ± 9
Adiponectin (μg/ml) 8.63 ± 3.56 9.06 ± 4.75 8.98 ± 4.16 6.46 ± 4.4 6.22 ± 3.98 6.43 ± 4.6
BP Systolic (mmHg) 119 ± 10 112 ± 12 122 ± 16 127 ± 22 131 ± 17 132 ± 16
BP Diastolic (mmHg) 71 ± 7 69 ± 10 77 ± 9 75 ± 11 80 ± 10 77 ± 5
Notes: Group 1 represents patients starting with rosuvastatin plus omega-3 PUFAs. Group 2 represents patients starting with rosuvastatin only. Data are presented as mean 
± SD. Statistically signiﬁ  cant differences are indicated with an asterisk.
Abbreviations: HDL, high-density lipoprotein; LDL, low-density lipoprotein; ESR, erythrocyte sedimentation rate; BP, blood pressure; PUFAs, polyunsaturated fatty 
acids; SD, standard deviation.
a vasoconstrictive response to shear stress. No studies to date 
have evaluated the effect of statins or omega-3 PUFAs on the 
endothelial function in this population.
Endothelial dysfunction is thought to be an early and impor-
tant event in the development of many cardiovascular diseases 
including atherosclerosis, hypertension, and heart failure. 
The precise mechanism of endothelial dysfunction is not 
completely understood, but it is generally believed to be mediated 
by NO produced by the endothelial cells. Other mediators such 
as prostanoids are also involved. The potential for reversal of 
endothelial dysfunction with different therapies has generated 
considerable interest. Previous studies have yielded conﬂ  ict-
ing results about the effect of statins on endothelial function. 
Several studies report that statin therapy improves endothe-
lial-dependent vasodilation in hypercholesterolemic patients 
(Leung et al 1993; Treasure et al 1995; Dupuis et al 1999). A Vascular Health and Risk Management 2008:4(6) 1445
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number of mechanisms have been proposed to explain these 
effects. One important pathway appears to be the effects of 
statins on NO production via increased availability of endo-
thelial nitric oxide synthase (eNOS). Thus, statins prevent the 
downregulation of eNOS mRNA by oxidized-LDL, hypoxia, 
and TNF-α (Hernandez-Perera et al 1998; Laufs et al 1998). 
Additionally HMG-CoA inhibition results in the activation of 
protein kinase Akt and the posttranslational phosphorylation 
of the eNOS protein (Dimmeler et al 1999; Fulton et al 1999). 
Nevertheless, other studies, particularly in subjects with type II 
diabetes, but also in patients with familial hypercholesterolemia, 
report no effect at all (Sheu et al 1999; Van de Ree et al 2001; 
van Etten et al 2002; ter Avest et al 2005). The reason for this 
inconsistency is unclear but could be related to the dependency 
of endothelial function on insulin resistance. There is also the 
possibility of a particular resistance to statins in South Asians 
and this ﬁ  nding deserves further investigation. Also, we cannot 
exclude a delayed vasodilative effect of rosuvastatin, but this is 
unlikely, as other studies have demonstrated a very early onset 
of the statin activity (Omori et al 2002). Similar ﬁ  ndings have 
been reported by ter Avest and colleagues (2005) who showed 
no effect of rosuvastatin on endothelial function, in spite of a 
clear effect on the lipid proﬁ  le and inﬂ  ammatory markers.
Long-chain omega-3 PUFAs, found in fatty ﬁ  sh and ﬁ  sh 
oil have cardiovascular protective properties. They cause 
endothelial relaxation and promote vascular compliance 
(Goode et al 1997; Tagawa et al 1999). Our study supports an 
early and consistent improvement in endothelium-dependent 
dilatation with treatment with the omega-3 PUFAs in South 
Asian patients with dyslipidemia treated with rosuvastatin 
(Figure 5). These ﬁ  ndings extend prior observations that 
omega-3 PUFAs improve endothelium-dependent dilatation 
in hypercholesterolemic patients (Engler et al 2004). The 
effect may be due particularly to the DHA component of the 
ﬁ  sh oil capsules (Mori et al 2000). The mechanism is not 
fully understood, but omega-3 PUFAs may protect against 
vasospasm and thrombosis by enhancing NO release, and pros-
tacyclin synthesis, and by suppressing thromboxane formation 
(McVeigh et al 1993).
Previously, it was proposed that omega-3 PUFAs mediate 
the actions of various statins and states of essential fatty acids 
deﬁ  ciency are accompanied by an increased HMG-CoA 
reductase activity, making statins unable to lower plasma 
lipid levels (Das 2001). These observations could explain 
why we found the improvement of endothelial function in 
the presence of omega-3-PUFAs.
The present study showed, for the first time, that 
omega-3 PUFAs improved endothelial function in a group 
of subjects who appeared resistant to the vasoprotective 
effect of rosuvastatin. These ﬁ  ndings support a therapeutic 
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Figure 5 Plotted results of endothelium dependent vasodilation percentage (EDV%) for each individual patient in group 1 and 2 between each visit. Group 1 represents 
patients starting with rosuvastatin plus omega-3 PUFAs, Group 2 represents patients starting with rosuvastatin only.Vascular Health and Risk Management 2008:4(6) 1446
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strategy where omega-3 PUFAs should be added to a statin, 
particularly if the endothelial function fails to improve.
Flow-mediated dilatation of the brachial artery correlates 
well with coronary response to the endothelium-dependent 
vasodilator acetylcholine. Therefore, the use of omega-3 
PUFAs supplements might possibly represent another thera-
peutic modality for patients with known, or at risk for coronary 
artery disease.
Our study conﬁ  rms prior reports from animal models 
showing omega-3 fatty acid supplementation improves EIV 
(Engler et al 1994). The improvement in EIV was seen in both 
groups but only as an effect of omega-3 PUFAs (Figure 3). 
The removal of omega-3 PUFAs from the treatment returned 
the EIV towards baseline. Engler and colleagues (1994) 
reported that in aortic rings from spontaneously hyperten-
sive rats and Wistar–Kyoto rats, EPA and DHA induced 
endothelium-dependent and-independent vasodilation, 
respectively. These may be attributable to direct and indirect 
effects of DHA on the arterial wall. The selective incorporation 
of DHA into endothelial membranes could increase membrane 
ﬂ  uidity, calcium inﬂ  ux, and endogenous synthesis and NO 
release. Although we did not see a signiﬁ  cant effect on the 
systolic or diastolic blood pressure, possibly because of 
the small sample size, EIV seems to be responsible for the 
improvement in blood pressure control with omega-3 PUFAs 
reported by others (Mori et al 2000).
This study is the ﬁ  rst to show that the beneﬁ  ts of omega-3 
PUFAs are rapidly lost with the withdrawal of treatment. 
Within 4 weeks of removal of omega-3 PUFA, the improvement 
in endothelial function was lost and the endothelial function, as 
measured by the EDV, returned to levels similar to the base-
line. Moreover, this signiﬁ  cant change in endothelial function 
was accompanied by worsening of EIV.
The use of statins is the standard of care for patients with 
dyslipidemia and at high risk for CAD. The study subjects 
exhibited an appropriate response to rosuvastatin (17%–25% 
reduction in LDL levels), which also conﬁ  rms their compli-
ance with the study medication. The addition of omega-3 
fatty acid supplements to rosuvastatin led to further decreases 
in LDL values and signiﬁ  cant decrease in the triglycerides 
levels. Nevertheless, none of the changes in the lipid proﬁ  le 
correlated to the change in the EDV/EIV, suggesting that 
the effect of omega-3 PUFAs on endothelial vasodilation is 
mediated via other mechanisms. Although there are reports 
of an effect of omega-3 PUFAs on the level of adiponectin 
in rats (Flachs et al 2006) we found no signiﬁ  cant alteration 
in the serum levels of adiponectin in our group of patients.
This study is limited particularly by the small sample size 
and by the relatively short period of treatment. Should these 
patients be treated longer, we could have possibly seen an 
effect of the rosuvastatin on the endothelial function. Nev-
ertheless, it is encouraging to see an early and strong effect 
of omega-3 PUFA when added to the statin. Other limitation 
of our study is the lack of control group treated with omega-
3-PUFAs only. Although our ﬁ  ndings strongly suggest that 
the improvement of endothelial function is due mainly to the 
omega-3-PUFAs, the results would have been more decisive 
having that control group.
In conclusion the addition of omega-3 PUFAs to 
rosuvastatin improves endothelial dependent and independent 
vasodilatation as well as further improves the lipid proﬁ  le in 
South Asians with dyslipidemia. These vasodilative effects 
are lost with the removal of omega-3 PUFAs. Population 
studies and clinical trials provide compelling evidence that 
omega-3 PUFAs have signiﬁ  cant cardioprotective effects and 
justify their use in the prevention of cardiovascular diseases. 
Table 3 Assessment of endothelial function by brachial artery ultrasound
Group 1 Group 2
Diameter (mm) Baseline 1st visit 2nd visit Baseline 1st visit 2nd visit
Resting 3.9 ± 0.6 3.7 ± 0.7 3.7 ± 0.7 3.7 ± 0.7 3.6 ± 0.6 3.1 ± 0.6
Post-ischemic
maximum
3.9 ± 0.5 4.1 ± 0.7 3.7 ± 0.7 3.6 ± 0.8 3.6 ± 0.7 3.6 ± 0.7
Absolute EDV −0.06 ± 0.13 0.41 ± 0.17* 0.007 ± 0.31 −0.09 ± 0.15 −0.006 ± 0.21 0.44 ± 0.31*
% EDV −1.42 ± 3.27 11.36 ± 4.33* 0.59 ± 8.32 −2.49 ± 4.16 −0.66 ± 6.44 14.73 ± 10.77*
Post-nitroglycerine 3.9 ± 0.8 4.2 ± 0.8 4.0 ± 0.7 3.9 ± 0.6 4.0 ± 0.7 4.0 ± 0.8
Absolute EIV 0.11 ± 0.23 0.59 ± 0.26* 0.3 ± 0.27 0.33 ± 0.32 0.38 ± 0.36 0.77 ± 0.33*
% EIV 3.4 ± 7.67 17.37 ± 9.27* 8.71 ± 7.67 10.31 ± 9.62 11.02 ± 10.43 24.5 ± 11.94*
Notes: Group 1 represents patients starting with rosuvastatin plus omega-3 PUFAs. Group 2 represents patients starting with rosuvastatin only. Data are presented as mean 
± SD. Statistically signiﬁ  cant differences are indicated with an asterisk.
Abbreviations: EDV, endothelial-dependent vasodilation; EIV, endothelial-independent vasodilation; PUFAs, polyunsaturated fatty acids; SD, standard deviation.Vascular Health and Risk Management 2008:4(6) 1447
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These beneﬁ  ts are achieved without the known side effects of 
other drug combinations. The present study also suggests that 
omega-3 PUFA’s are not only effective triglyceride-lowering 
agents but also improve endothelial function in a group of 
subjects resistant to the vasoactive effect of rosuvastatin.
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